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Abstract 
We estimate treatment cost-savings from early cancer diagnosis.  
For breast, lung, prostate and colorectal cancers and melanoma, 
which account for more than 50% of new incidences projected in 
2017, we combine published cancer treatment cost estimates by 
stage with incidence rates by stage at diagnosis.  We extrapolate 
to other cancer sites by using estimated national expenditures 
and incidence rates.  A rough estimate for the U.S. national annual 
treatment cost-savings from early cancer diagnosis is in 11 digits.  
Using this estimate and cost-neutrality, we also estimate a rough 
upper bound on the cost of a routine early cancer screening test. 
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1. Introduction 
According to the Centers for Medicare & Medicaid Services (CMS), in 2015 the U.S. national 
health expenditure (NHE) was $3.2 trillion and accounted for 17.8% of Gross Domestic Product 
(GDP); NHE is projected to grow at an average rate of 5.6% per year in 2016-2025 [CMS, 2017].  
Cancer care is projected to account for up to $177 billion in 2017 [NCI, 2017b], or nearly 1% of 
GDP.5  American Cancer Society estimates 1.7 million new cases of cancer and 600 thousand 
deaths in 2017 [ACS, 2017].  Although overall incidence rates for new cancer cases have been 
falling on average 1.1% each year over the last 10 years and death rates have been falling on 
average 1.5% each year over 2005-2014 [NCI, 2017d], the impact of population changes in the 
U.S. on cancer prevalence may exceed the impact of declining cancer incidence rates.  Also, the 
population in the U.S. is expected to become much older: by 2030, more than 20% of the U.S. 
residents are projected to be aged 65 and over, compared with 13% in 2010 [Ortman et al, 
2014].  Since cancer incidence typically is higher in the elderly, the aging population and costly 
advancements in treatment options will impact cancer survival and care expenditures, both of 
which are likely to increase in the future.  Overall, the cancer costs do tend to rise [NCI, 2017b]. 
Detecting and treating cancer at an early stage can and does save lives.  Survival rates 
improve dramatically when cancer is diagnosed early and the disease is confined to the organ 
of origin, before it has had a chance to spread and is more likely to be treated successfully [Cho 
et al, 2014], [Aravanis et al, 2017].  Conversely, a late stage diagnosis essentially means that the 
cancer has spread making treatment much more difficult, thereby reducing chances of survival.  
Thus, according to [Cancer Research UK, 2017]: more than 9 in 10 bowel cancer patients will 
survive the disease for more than 5 years if diagnosed at the earliest stage; more than 90% of 
women diagnosed with breast cancer at the earliest stage survive their disease for at least 5 
years compared to around 15% for women diagnosed with the most advanced stage of disease; 
more than 90% of women diagnosed with the earliest stage ovarian cancer survive their disease 
for at least 5 years compared to around 5% for women diagnosed with the most advanced 
stage of disease; around 70% of lung cancer patients will survive for at least a year if diagnosed 
at the earliest stage compared to around 14% for people diagnosed with the most advanced 
stage of disease.  The importance of diagnosing cancer early for survival cannot be overstated.  
Another important aspect relating to early diagnosis is treatment costs.  Thus, cancer 
patient costs of care in the last year of life are sizably higher than during earlier stages [NCI, 
2017c].  Further, in many cases, it is much less costly to treat cancer when it is diagnosed early.6  
                                                          
5
 The $177B figure is a high estimate assuming incidence/survival rate trends and 5% cost increases [NCI, 2017b].  
  
6
 E.g., for later-stage melanoma, chemotherapy, etc., sizably increase costs [Styperek and Kimball, 2012] (see Table 
V therein). 
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Considering that the wealth of nations is not limitless, one of our better chances to reduce 
staggering cancer treatment costs is through early detection and intervention.  Traditionally, 
cancer research has focused on treatments for late-stage disease, encompassing an estimated 
85% of the annual allocation [Curry et al, 2003].  Thus, global oncology drug costs reached $107 
billion in 2015 and are projected to exceed $150 billion by 2020 [Buffery, 2016].  Such trends 
appear to be producing a shift in thinking amongst various stakeholders, such as policy makers, 
payers, providers, and consumers, in reorienting research toward prevention7 and early 
detection.  Recent high fund-raising figures by companies such as Grail, Inc., which raised close 
to $1B in its recent series B funding round [Nasdaq GlobeNewswire, 2017], and Guardant 
Health, which recently raised $360M from investors (bringing its total raised to $550M) 
[Herper, 2017] speak volumes in this regard.  Therefore, here we ask the following question: 
What are the estimated cost-savings from early cancer diagnosis?  Our goal is to arrive at a 
conservative estimate.  Therefore, we define cost-savings from early diagnosis by assuming that 
all stage III and IV cases are detected at stages I or II, with the current incidence rates therefor.  
We specifically exclude stage 0.  The requisite data is scarce, incomplete and scattered.  We use 
costs and incidence rates data available for 4 and 19 cancer sites, respectively, and extrapolate 
to various other cancers.  We focus on the U.S. expenditures.  While healthcare costs in other 
countries are in many cases lower than in the U.S., the estimates apply directionally worldwide.  
Finally, the cost-savings estimates hereof are limited to direct costs for treatment only.  When 
conducting health economic analyses, a critical piece of the evaluation is the question “what is 
the value of health, both to the individual patient and to the overall system as a whole?”  In 
considering this question, indirect financial costs of cancer treatment can be an additional 
burden to the people diagnosed with cancer, their families, their employers, and the society in 
general, and the added costs can be significant.  However, as mentioned above, we are after a 
conservative estimate and such considerations would only add to it.  Our estimate, $26B/year, 
is by no means “precise” as it is extrapolated.  However, it is likely correct within a factor of 2.   
The remainder is organized as follows.  Section 2 discusses i) a methodology for estimating 
cost-savings from early cancer diagnosis and ii) data based on commercial claims for breast 
cancer as reported in [Blumen et al, 2016] and on incidence rates by stage at diagnosis as 
reported in [Iqbal et al, 2015].  Section 3 discusses incidence rate data for 19 cancer sites as 
reported in [Morris et al, 2013] (and also [Parikh-Patel et al, 2015]).  Section 4 discusses 
Medicare claims data as reported in [Schrag, 2015] for 4 cancer sites.  Section 5 discusses 
melanoma data as reported in [Styperek and Kimball, 2012].  Section 6 discusses i) 
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 Reducing exposure to known carcinogens [Loeb and Harris, 2008], [Ananthaswamy and Pierceall, 1990] such as 
tobacco, etc., is important.  However, cancer occurs at the DNA level via somatic mutations (see [Goodman and 
Fygenson, 1998], [Lindahl, 1993], [Tomasetti et al, 2017] and referenced therein) and is not always preventable.   
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extrapolation to other cancer sites and ii) national expenditure estimates as reported in [NCI, 
2017b].  Section 7 briefly concludes.  Tables 1 through 11 contain data utilized in our analysis. 
2. Breast Cancer   
2.1. Costs by Stage at Diagnosis: Commercially Insured Population Study 
Blumen et al [2016] analyze commercially insured U.S. women aged 18 to 64 years who 
were newly diagnosed with breast cancer in 2010.8  Table 1, which is adapted from [Blumen et 
al, 2016], summarizes their results.  The average per-patient allowed costs in the 12 months 
following diagnosis are $60,637, $82,121, $129,387 and $134,682 for stages 0, I/II, III, and IV at 
diagnosis, respectively.  The average per-patient allowed costs in the 24 months following 
diagnosis are $71,909, $97,066, $159,442 and $182,655 for stages 0, I/II, III, and IV at diagnosis, 
respectively.  These costs are not adjusted for inflation or any other temporal changes. 
 2.2. Incidence Rates by Stage at Diagnosis 
Iqbal et al [2015] analyze various data for 452,215 women diagnosed with invasive breast 
cancer from 2004 to 2011 who were identified in the Surveillance, Epidemiology, and End 
Results (SEER) 18 registries database.9  This study focuses on stages I, II, III and IV, specifically 
excluding in situ stage 0 and stage unknown cases.10  Table 2, which is adapted from [Iqbal et al, 
2015], summarizes the data for breast cancer incidence rates (in %) by stage (I, II, III and IV only) 
at diagnosis, including aggregated numbers as well as those broken down by eight racial/ethnic 
groups, across which there is some degree of variability, which should be kept in mind when 
interpreting cost-savings estimates.  We will use the figures (column 2, Table 2) aggregated 
across all racial/ethnic groups:  48%, 34.6%, 12.4% and 5% for stages I, II, III and IV, respectively. 
                                                          
8
 This study utilizes the Truven Health MarketScan® commercial claims database using 2010 as the index year, 2009 
as a look-back year, and 2011 and 2012 as the 24-month look-forward period.  It infers the stage – to wit, stage 0, 
I/II, III, or IV – at diagnosis based on identification of stage-specific treatments recommended in the National 
Comprehensive Cancer Network (NCCN) treatment guidelines [NCCN, 2017].  Cases at stages I and II are combined 
as the NCCN treatment recommendations are interchangeable for these stages.  See [Blumen et al, 2016] for 
details. 
 
9
 According to [NCI, 2017a]: the SEER 18 registries consist of the SEER 13 plus Greater California, Greater Georgia, 
Kentucky, Louisiana, and New Jersey; the SEER 13 registries consist of the SEER 9 plus Los Angeles, San Jose-
Monterey, Rural Georgia and the Alaska Native Tumor Registry; the SEER 9 registries are Atlanta, Connecticut, 
Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, and Utah. The SEER 18 covers 
about 28% of the total U.S. population (based on the 2010 Census) [Iqbal et al, 2015]. 
 
10
 It also excludes a small fraction of cases with borderline, undetermined or unknown estrogen receptor status, 
and those with prior history of any cancer, leaving 373,563 cases in the study [Iqbal et al, 2015]. 
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2.3. Cost-Savings Estimates   
To estimate cost-savings of early (stages I and II) vs. late (stages III and IV) diagnoses, we use 
the 12-month and 24-month average per-patient allowed costs for stages I/II, III and IV from 
Blumen et al [2016] (see Subsection 2.1 and columns 4 and 6 of Table 1) and incidence rates by 
stage at diagnosis (see Subsection 2.2 and column 2 in Table 2) from [Iqbal et al, 2015].  The 
average 12- and 24-month estimated per-patient cost-savings from early diagnosis are given by  
                                                                                        
                                                                                          
Here              ,               and              are the 12-month average per-
patient allowed costs for stages I/II, III and IV, respectively;              ,               
and              are the 24-month average per-patient allowed costs for stages I/II, III and 
IV, respectively.  The incidence rates by stage at diagnosis are          ,          , 
           and          for stages I, II, III and IV, respectively.  Thus, in Eq. (1) and Eq. (2) 
we are estimating average savings by assuming that all stage III and IV cases are diagnosed 
early, at stage I or II.  With these assumptions, the estimated cost-savings are               
and                (these figures are rounded to the nearest integer).  It is also instructive 
to estimate relative (as opposed to absolute) cost-savings compared with average per-patient 
costs across all stages.  The latter can be estimated as  
                                                                               
                                                                                
These estimates,                and                , are based on stage I, II, III 
and IV cases only.  However, if we include in situ stage 0 cases, then the average per-patient 
costs are lower.  To estimate these costs, we need the incidence rate for stage 0 cases.  Thus, 
according to [Siegel et al, 2017], the estimated number of new in situ (stage 0) female breast 
cancer cases in the U.S. in 2017 is 63,410, whereas the estimated number of new invasive 
(stages I, II, III and IV) female breast cancer cases in the U.S. in 2017 is 252,710.  We will take 
                                        as the incidence rate for stage 0.  Accordingly, 
the incidence rates for stage I-IV cases are given by                 with             .  
Note that                     , and, therefore,                             . 
The average per-patient costs across all stages including stage 0 then are given by 
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Here             and            (see Subsection 2.1), so                 and 
                , which are 6.6% and 6.8% lower than        and       , respectively.  
The relative cost-savings are defined as 
                                                                                    
                                                                                    
                                                                                  
                                                                                
These estimated relative cost-savings are             ,              ,         
     ,              .  So, roughly, we expect around 8-11% savings from early diagnosis.  
When we include stage 0, in Eq. (9) and Eq. (10) the average 12- and 24-month estimated per-
patient cost-savings         and         are computed via Eq. (1) and Eq. (2), respectively, but 
with      and     replaced by       and     , hence the factor         .  Therefore, including 
stage 0 reduces the absolute costs-savings and also to a lesser degree the average costs, so 
overall the relative cost-savings are also reduced.  Thus, we have                        , 
and                         , so including stage 0 reduces the relative cost-savings by 
about 14-15%.  Generally, stage unknown can also alter these figures, but to a lesser degree.  
3. Incidence Rates by Stage at Diagnosis: 19 Cancers 
Morris et al [2013] provide detailed data for stage at diagnosis for California adults aged 20 
and older diagnosed with cancer during 2005-2009.  Their data contains 19 cancer sites.  We 
compile their data into Table 3, which provides (for each of the 19 cancer sites) the total 
number of cases, numbers of cases for stages 0-IV and stage unknown, and the corresponding 
incidence rates (in %), both including and excluding stage 0 and stage unknown.  For some 
cancer sites stage 0 data is not available (NA).  For bladder stage 0 and stage I are combined. 
Comparing incidence rates in columns 15-18 of Table 3 (these correspond to stages I-IV 
only, with stage 0 and stage unknown excluded) for breast cancer, we see that they are very 
close to the incidence rates in column 2 of Table 2 obtained from [Iqbal et al, 2015], which is 
based on the SEER 18 database (see Subsection 2.2) and includes various other U.S. regions. 
Morris et al [2013] also provide data for various racial/ethnic and age groups.  We compile 
their data for breast cancer into Table 4.  The last 4 rows correspond to the incidence rates by 
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stage at diagnosis with stage 0 and stage unknown excluded.  The racial/ethnic group incidence 
rates are consistent with those in Table 2, which are based on the SEER 18 [Iqbal et al, 2015]. 
3.1. A Sanity Check: 5 Cancers   
Parikh-Patel et al [2015] analyze data by stage at diagnosis, quality of treatment, and 
survival among persons diagnosed with breast, colon, rectal, lung, and prostate cancer in 
California between 2004 and 2012.  We compile their data into Table 5.  The last 4 columns of 
Table 5 are consistent with those in Table 3.  A notable difference exists for prostate cancer, for 
which there are relatively few cases at stage I in Table 3, and a more sizable number in Table 5, 
but the stage I + II incidence rates from Table 3 (85.5%) and Table 5 (84.64%) are still consistent. 
4. Medicare Data: 4 Cancers 
Schrag [2015] provides Medicare spending estimates for breast, colorectal, lung and 
prostate cancers in California between 2007-2011.  One of the reasons cited in [Schrag, 2015] 
for focusing on Medicare spending is that “Medicare data, unlike data from other payers, are 
readily accessible”.  We compile the data from [Schrag, 2015] into Table 6 (mean per-patient 
Medicare spending in the first year after diagnosis by stage at diagnosis) and Table 7 (mean per-
patient Medicare spending in the last year of life by stage at diagnosis).  The costs in Table 7 in 
the last year of life are relatively uniform with the stage at diagnosis.  However, the costs in 
Table 6 in the first year after diagnosis increase considerably with the stage at diagnosis. 
For the first year after diagnosis, we can use the same methodology as in Subsection 2.3 to 
estimate cost-savings from early (stages I and II) vs. late (stages III and IV) diagnosis.  Here we 
can estimate the following quantities:        (average per-patient cost in the first 12 months 
after diagnosis based on stages I-IV) using Eq. (3);        (average per-patient cost-savings 
from early diagnosis in the first 12 months from diagnosis) using Eq. (1); and        (the 
relative cost-savings) using Eq. (7).  In Eq. (1) and Eq. (3) the quantity (the stage I/II cost) 
                                                                                 
Here    is the stage  cost from Table 6 (columns 2-5), and    is the stage  fraction from 
Table 6 (columns 6-9) with             .  For prostate cancer we set     , so          .   
The results are summarized in Table 8.  For breast cancer the relative savings (11.35%) are 
consistent with our estimates in Subsection 2.3 for commercially insured patients.  Note that 
the fractions in columns 6-9 of Table 6 are somewhat different from all-age incidence rates in, 
e.g., Table 3.  For instance, for breast cancer in Table 6 we have 52% for stage I, while in Table 3 
we have about 48%.  This difference appears to be due to the age group (Medicare).  Thus, for 
age 65+ we have the incidence rate close to 54% for breast cancer in Table 4.  Also, let us note 
8 
 
that the average per-patient costs reported in [Schrag, 2015] in the graph at p.9 are somewhat 
lower11 than those in column 2 of Table 8 (which are computed based on the data in Table 6 as 
set forth above).  This difference may be due to stage 0 and/or stage unknown contributions.  
There is not enough information to determine this; however, the difference is small (< 7.52%). 
Finally, let us mention that our estimate for the average 12-month cost for breast cancer for 
Medicare (see Table 8) is $38,130, while the analogous estimate for the commercially insured 
population from Subsection 2.3 is $90,610, i.e., the Medicare figure is about 42% of the 
commercial insurance figure.12  However, this ratio is by no means “precise” as the commercial 
insurance figures in [Blumen et al, 2016] are from 2010 diagnoses, whereas the Medicare data 
in [Schrag, 2015] is from 2007-2011 diagnoses, so the actual ratio could be higher.  However, 
the ballpark appears to be correct.  Thus, according to Appendix D of [Pyenson et al, 2016],13 in 
2004 the cancer population was 63,935 (commercial), and 118,089 (Medicare), while the total 
spending (allowed) in this population was $2,281,981,711 (commercial) and $2,619,153,436 
(Medicare), so the per-patient spending in 2004 was $35,692 (commercial) and $22,179 
(Medicare), and the corresponding Medicare-to-commercial ratio was about 62%.  According to 
this source, in 2014 the cancer population was 264,204 (commercial), and 133,225 (Medicare), 
while the total spending (allowed) in this population was $13,908,337,950 (commercial) and 
$3,672,799,298 (Medicare), so the per-patient spending in 2014 was $52,642 (commercial) and 
$27,568 (Medicare), and the corresponding Medicare-to-commercial ratio was about 52%.  So, 
the rough ratio for breast cancer we obtained above from the [Blumen et al, 2016] and [Schrag, 
2015] data is in the ballpark of those based on the [Pyenson et al, 2016] data (for all cancers).14 
5. Melanoma 
Styperek and Kimball [2012] provide malignant melanoma costs by stage at diagnosis based 
on 2008 data.15  Based on [Styperek and Kimball, 2012], we compile the costs in the first year 
after diagnosis and incidence rates by stage at diagnosis in Table 9.  As in the previous section, 
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 To wit, $35,264 for breast cancer, $28,213 for prostate cancer, $78,444 for lung cancer, and $69,687 for 
colorectal cancer.  [Schrag, 2015] cites “CCR-Medicare, 2014 data linkage, Healthcare Delivery Research Program, 
National Cancer Institute” as the source for these average spending figures. 
 
12
 The $35,264 figure from [Schrag, 2015] (see fn.11 hereof), divided by                 (see Subsection 2.3) 
gives 41.7%. 
  
13
 Based on Milliman analysis of the 2004-2014 Truven Health MarketScan® data and Medicare 5% sample data.  
 
14
 The aforesaid Medicare (based on [Schrag, 2015]) and commercial (based on [Blumen et al, 2016]) data are not 
necessarily uniformly normalized.  On the other hand, we expect that the Medicare and commercial figures from 
Appendix D of [Pyenson et al, 2016] are uniformly normalized and can be meaningfully compared with each other. 
 
15
 There is a variability in costs reported in various studies [Guy Jr et al, 2012].  Also see [Alexandrescu, 2009].  
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we can estimate the following quantities:        (average per-patient cost in the first 12 
months after diagnosis based on stages I-IV) using Eq. (3);        (average per-patient cost-
savings from early diagnosis in the first 12 months from diagnosis) using Eq. (1); and        
(the relative cost-savings) using Eq. (7).  In Eq. (1) and Eq. (3) the quantity (the stage I/II cost) 
      is given by Eq. (11).  Using the data for stages I-IV in Table 9, we have               , 
              and              .  Such a dramatic cost reduction from early diagnosis 
is due to more than a 3-fold increase in melanoma treatment costs between stages II and III. 
Using the melanoma incidence rates from Table 3, we would get a higher              . 
6. Extrapolating to Other Cancers 
6.1. Relative Cost-Savings   
Using the definitions in Eq. (1), Eq. (3) and Eq. (7), we can rewrite the relative cost-savings 
       as follows: 
                                                                                 
                                                                                 
Here                          is the incidence rate of late-stage (stages III and IV) 
diagnosis, and  
                                                                                  
We define                                           , and              is defined 
in Eq. (11).  Therefore, the relative-cost savings are controlled by two parameters,       and  . 
We summarize these quantities in Table 10 for breast cancer (based on the commercial 
claims data from [Blumen et al, 2016] and the Medicare data from [Schrag, 2015]), prostate, 
lung and colorectal cancers (based on the Medicare data from [Schrag, 2015]), and melanoma 
(based on the data from [Styperek and Kimball, 2012]).  There is a substantial heterogeneity in 
both       and  , including in commercial vs. Medicare data.  Lung cancer has higher 
              largely due to it mostly being diagnosed late (         ).  On the other 
hand, melanoma has really high               mainly due to a large jump in the treatment 
costs between early (             ) and late (             ) diagnoses.  In contrast, for 
prostate cancer we have low              due low           as well as low       . 
Table 3 contains incidence rates by stage at diagnosis for 19 cancer sites.  We will use this 
data for cancer sites (for which cost data is available – see below)16 beyond the 5 cancers we 
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 E.g., cost data are available for colorectal cancer, not for colon cancer or rectum carcinoma separately; etc. 
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discuss above.  For such cancer sites we will use the mean value of       based on the last 2 
columns of Table 3.  This mean value is               with a standard deviation
17 = 21.04%. 
To estimate   via Eq. (13), we also need the values of  .  For breast, prostate, lung and 
colorectal cancers and melanoma, we will take these values from Table 10.  Conservatively, for 
breast cancer we will take the lower value from row 2 of Table 10.  For cancer sites beyond 
these 5, we must estimate  .  We exclude row 3 (the higher value of   for breast cancer) and 
row 7 (melanoma, which is an outlier).  The remaining 4 values of   (rows 2 and 4-6 in Table 10) 
have the mean of 0.5202 and the median of 0.5232.  We will set       02 for the other sites. 
6.2. Estimated National Expenditures   
Estimated national expenditures between 2010 and 2020 are provided in [NCI, 2017b]18 for 
17 cancer sites (which are not the same as those in Table 3).  Detailed data can be downloaded 
from the webpage referenced in [NCI, 2017b].  For each year, including 2017 which we focus 
on, this data contains 6 numbers for the estimated national expenditures based on 6 different 
assumptions, to wit: i) both incidence and survival are constant; ii) incidence follows recent 
trends, survival is constant; iii) survival follows recent trends, incidence is constant; iv) both 
incidence and survival follow recent trends; v) both incidence and survival follow recent trends, 
annual costs increase at 2% (applied to initial and last phases);19 vi) both incidence and survival 
follow recent trends, annual costs increase at 5% (applied to initial and last phases).  In i)-iv) 
above annual costs are assumed to be constant.  For estimated national costs for 2017 we take 
the mean of these six figures, and the so-averaged figures are in column 2 of Table 11, while the 
corresponding standard deviations (in %) are in column 3 thereof.  These standard deviations 
are reasonably small.  For the cancer sites in column 1 of Table 11 we also give the expected 
2017 new incidence rates (as reported in [ACS, 2017] and [Siegel et al, 2017]) in column 4.  
Dividing column 2 by column 4 produces column 5, the per-new-incidence estimated costs.20  
Columns 6-8 list the values of  ,       and        as set forth above (also see the caption to 
Table 11).  We then roughly estimate national cost-savings      from early diagnosis via   
                                                                               
                                                                                
                                                          
17
 For the same data in Table 3, median = 42.4% and MAD = 28.9% (MAD = mean absolute deviation).  Below we 
will use the lower mean value               and not the higher median value for our conservative estimate. 
 
18
 Also see [NCI, 2017c].  
 
19
 Initial phase = initial year after diagnosis; last phase = last year of life; continuing phase = in-between period.    
For detailed information about the methods, data sources and assumptions in [NCI, 2017b], see [Mariotto, 2011]. 
 
20
 Which are not the same as the per-patient costs.  We give column 5 in Table 11 for orientation purposes.  
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Here the factor  corrects for the stage 0 contributions (see Subsection 2.3).  For breast 
cancer we take         (see Subsection 2.3).  For melanoma, using            from 
Table 3,         from Table 9, and                from Section 5, we get        , 
so the reduction due to stage 0 is small despite a large     as the stage 0 cost    is small.  For 
other cancer sites     is sub-10% (or NA) and assuming that    is sizably smaller than        
(see Subsection 2.3), for these cancer sites  is expected to be close to 1.  The results for 
estimated national costs-savings      are in column 9 of Table 11 (and the national cost 
estimates      are taken from column 2 thereof).  The factor  is set to        for breast 
cancer, and to 1 for other cancer sites.  The all-sites national cost-savings estimate is $26B. 
6.3. Caveats   
Our estimates are clearly far from being “precise” for a variety of reasons, including 
extrapolating   and       to various cancer sites based on data available for 4 and 19 cancer 
sites, respectively.  However, we have taken a conservative approach to so-extrapolating  .  
Nonetheless, e.g., for certain cancers cost-savings from early diagnosis may be less attainable 
than from others.21  Also, in Eq. (15) we simply use        (estimated relative cost-savings for 
the first year after diagnosis).22  The last phase (the last year of life) costs are skewed toward 
higher figures (see, e.g., [NCI, 2017c]) due to added expenses at this phase.  However, with 
early diagnosis the survival rate would also go up thereby decreasing the contribution of the 
last phase to the overall costs.  Another caveat is that commercial insurance vs. Medicare vs. 
other payer costs are heterogeneous (and the corresponding data is not readily available), the 
costs have strong temporal dependence as new treatments become available continuously (and 
most available data is at least some years out-of-date), etc., so cost-estimates are uneven (see, 
e.g., [Guy Jr. et al, 2012]).  However, the $26B figure above is likely correct within a factor of 2.  
7. Conclusions 
The above rough estimate for cost-savings from early cancer diagnosis, $26B, is only about 
17% of the total estimated expenditures (see Table 11) and appears to be reasonable despite 
various built-in (conservative) extrapolations.  If we take breast, lung, prostate and colorectal 
cancers and melanoma, which are top 5 cancers by incidence with the total 859,110 estimated 
new cases in 2017, which amounts to 50.87% of all 1,688,780 estimated new cases across all 
                                                          
21
 Let us note a minor caveat that for bladder cancer the stage 0 and stage I figures in Table 3 are combined.   
 
22
 Albeit adjusted for stage 0 contributions via the factor   (see above).  Also, note that the rates        and 
       are consistent with each other (see the discussion after Eq. (10) in Subsection 2.3), so using the        
rates in our extrapolated estimations is reasonable.  A more important caveat is related to the last year of life 
costs, which are skewed, and which we discuss below in this Subsection. 
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cancer sites,23 the estimated costs add up to over $67B (or about 43.87% of costs for all sites), 
and the corresponding estimated cost-savings from early diagnosis add up to over $10.7B (or 
about 41.49% of cost-savings for all sites).  Again, these figures should be considered keeping in 
mind the caveats we discuss above.  Even assuming only 50%, the cost-savings are staggering.24 
Above we focus on the U.S.  Cost-savings from early cancer diagnosis in some other regions 
of the world have been addressed in the literature.  Here we will not attempt an exhaustive 
review.  Instead, keeping in mind that generally healthcare costs in other countries are in many 
cases lower than in the U.S., let us mention a U.K. study [Incisive Health, 2014]25 and a shorter 
summary thereof [Birtwistle, 2014], according to which the fractions of the costs for stage I vs. 
stage IV at diagnosis for colon, rectal, ovarian and lung cancers are approximately 27.2%, 
37.3%, 35.1% and 61.1%, respectively.  Again, cost-savings from early diagnosis are staggering. 
It is precisely these economic considerations that underlie recent high fund-raising figures 
by companies such as Grail, Inc., which raised close to $1B in its recent series B funding round 
[Nasdaq GlobeNewswire, 2017], and Guardant Health, which recently raised $360M from 
investors (bringing its total raised to $550M) [Herper, 2017].  These figures may appear inflated 
at first, but are not unreasonable based on the estimated annual cost-savings we discuss here.  
Early cancer diagnosis does not only save lives but will also save billions of dollars in costs. 
In this regard, we can estimate a rough upper bound on the cost of a routine early cancer 
screening test.  We have estimated $26B/yr in savings from early cancer diagnosis.  According 
to [Mehrotra et al, 2007], there were about 44.4M adults annually who received preventive 
health examinations during 2002-2004.  Let us take this figure as a rough estimate for the 
number of annual early cancer screening tests.  Then on a cost-neutral basis an approximate 
upper bound for the cost of such a test is $600.  Let us note that this estimate could actually be 
lower or higher depending on various details.  First, our $26B/yr estimate is conservative and 
the actual cost-savings could be higher.  Second, this estimate is extrapolated to all cancer sites.  
Early screening tests may apply to a limited number of cancer sites, and the available cost-
savings would be lower.  However, if so, then the number of patients screened may also be 
limited to those at risk, which would decrease the number of tests administered.  Third, as 
                                                          
23
 These figures relate to invasive cancer incidences.  Thus, in addition, e.g., about 63,410 cases of female breast 
cancer in situ and 74,680 cases of melanoma in situ are expected to be diagnosed in 2017 [Siegel et al, 2017]. 
 
24
 Also, as mentioned above, here we are not including indirect costs of cancer or considerations stemming from 
the quality-adjusted life-years (QALY), etc.  Again, our goal here is to arrive at a reasonable conservative estimate. 
 
25
 Also, see, e.g., [Laudicella et al, 2016]. 
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mentioned above, we are not including indirect costs of cancer or considerations stemming 
from the quality-adjusted life-years (QALY), etc., which may also increase said upper bound.26 
Let us emphasize that, here our goal is not to determine cost-savings from any particular 
early cancer screening (be it blood-based or any other such) test.  Realistically, all such tests are 
expected to have false negatives and false positives.  Clearly, false negatives would decrease 
any cost-savings associated with early cancer detection.  However, if the rate of false negatives 
is too high to begin with, such a test may not be viable in the first instance.  On the other hand, 
false positives could increase costs as they may cause unnecessary additional testing and/or 
treatment, not to mention all the anxiety and stress to the patients misdiagnosed with cancer 
by such false positives.  Again, if the rate of false positives is too high to begin with, such a test 
may not be viable in the first instance.  Without specific and reliable data (which does not exist 
yet) from, say, blood tests, it is virtually impossible to intelligently estimate the effects of false 
positives or negatives and such an estimate would at best be highly speculative and likely 
uninformative.  Thus, currently it is unknown what the rates of false positives or negatives will 
be for new cancer screening technologies such as ctDNA (circulating tumor DNA) based blood 
tests – these technologies are still in nascent stages [Aravanis et al, 2017].  Instead, our goal 
here is to conservatively estimate the size of cost-savings from early detection (which is roughly 
the size of the “market”, which affects the pricing of early detection tests as discussed above).  
Our estimate is only rough for the multitude of reasons discussed in detail above and our 
$26B/yr figure likely is accurate within a factor of 2.  However, this figure is reasonable and 
there is value in knowing the order of magnitude of the available cost-savings.  Thus, from our 
analysis it is clear that these cost-savings should be much larger than, say, $1-2B/yr, but at the 
same time they are unlikely to lead to 50% overall cost reduction (this, among other things, is 
due to high-incidence-level cancers such as prostate and breast cancers already being 
diagnosed early in many cases based on currently available screenings such as mammograms 
and prostate exams).  However, by piecing together scattered (and not-so-readily available) 
data and being conservative, our estimates appear to be reasonable and in line with others (see 
fn.26). 
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Tables 
Stage at 
diagnosis 
# of patients 
at diagnosis 
0-6 months 
postdiagnosis 
0-12 months 
postdiagnosis 
0-18 months 
postdiagnosis 
0-24 months 
postdiagnosis 
0 2300 $48,477 $60,637 $67,450 $71,909 
I/II 4425 $61,621 $82,121 $91,109 $97,066 
III 1134 $84,481 $129,387 $147,470 $159,442 
IV 501 $89,463 $134,682 $162,086 $182,655 
All 8360 $62,774 $85,772 $96,499 $103,735 
Table 1. Average per-patient allowed costs, by disease stage at diagnosis, for breast cancer 
patients studied in [Blumen et al, 2016]. 
 
Stage at 
diagnosis 
Total Non-
Hispanic 
White 
Hispanic 
White 
Black Chinese Japanese South 
Asian 
Other 
Asian 
Other  
I 48.0 50.8 40.1 37.0 50.1 56.1 40.4 45.2 43.6 
II 34.6 33.2 38.7 38.6 35.7 32.4 38.7 38.1 37.2 
III 12.4 11.4 15.9 16.6 10.7 8.5 15.3 12.4 13.5 
IV 5.0 4.6 5.3 7.8 3.5 3.0 5.6 4.3 5.7 
Table 2. Breast cancer incidence rates (in %) by stage at diagnosis from 2004 to 2011 for 
women who were identified in the Surveillance, Epidemiology, and End Results (SEER) 18 
registries database, as reported in [Iqbal et al, 2015].  Columns 3-10 correspond to the eight 
racial/ethnic groups identified therein.  Column 2 corresponds to all racial/ethnic groups.  
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Cancer Total, # Stage 
0, # 
Stage 
I, # 
Stage 
II, # 
Stage 
III, # 
Stage 
IV, # 
Stage 
?, # 
Stage 
0, % 
Stage 
I, % 
Stage 
II, % 
Stage 
III, % 
Stage 
IV, % 
Stage 
?, % 
Stage 
I, % 
Stage 
II, % 
Stage 
III, % 
Stage 
IV, % 
Breast 141654 27344 51515 37083 13360 5415 6937 19.3 36.37 26.18 9.43 3.82 4.9 47.98 34.54 12.44 5.04 
Cervix 7454 NA 3516 894 1402 942 700 NA 47.17 11.99 18.81 12.64 9.39 52.06 13.23 20.76 13.95 
Colon 55378 4872 11342 13393 12000 9849 3922 8.8 20.48 24.18 21.67 17.79 7.08 24.35 28.74 25.76 21.15 
Rectum 22468 2045 5132 3825 4631 3406 3429 9.1 22.84 17.02 20.61 15.16 15.26 30.2 22.5 27.25 20.04 
Esophagus 6786 118 1098 959 1063 2154 1394 1.74 16.18 14.13 15.66 31.74 20.54 20.82 18.18 20.15 40.84 
Kidney 23664 373 12100 2193 3084 4070 1844 1.58 51.13 9.27 13.03 17.2 7.79 56.42 10.23 14.38 18.98 
Larynx 4803 402 1647 644 606 1080 424 8.37 34.29 13.41 12.62 22.49 8.83 41.41 16.2 15.24 27.16 
Liver 15246 NA 3964 2126 2682 2433 4041 NA 26 13.94 17.59 15.96 26.51 35.38 18.97 23.94 21.72 
Lung 86954 34 14847 3083 18639 37467 12884 0.04 17.07 3.55 21.44 43.09 14.82 20.05 4.17 25.18 50.61 
Melanoma 59676 23920 22250 3990 1910 1355 6251 40.08 37.28 6.69 3.2 2.27 10.47 75.39 13.53 6.47 4.59 
Oral 18434 445 3272 2074 2463 6415 3765 2.41 17.75 11.25 13.36 34.8 20.42 23 14.58 17.31 45.1 
Ovary 14295 NA 3427 870 3984 2995 3019 NA 23.97 6.09 27.87 20.95 21.12 30.39 7.72 35.33 26.56 
Pancreas 19545 77 1248 3995 1331 9054 3840 0.39 6.39 20.44 6.81 46.32 19.65 7.99 25.56 8.52 57.93 
Prostate 109601 NA 134 84673 7283 7097 10414 NA 0.12 77.26 6.65 6.48 9.5 0.13 85.37 7.35 7.16 
Stomach 13566 140 2855 1269 1319 5014 2969 1.03 21.05 9.35 9.72 36.96 21.89 27.31 12.13 12.61 47.95 
Testis 4809 11 3249 454 717 0 378 0.23 67.56 9.44 14.91 0 7.86 73.51 10.27 16.22 0 
Thyroid 17968 NA 11375 1466 2134 1890 1103 NA 63.31 8.16 11.88 10.52 6.14 67.45 8.69 12.66 11.21 
Bladder 31628 --- 22875 3434 1401 2331 1587 --- 72.33 10.86 4.43 7.37 5.02 76.15 11.43 4.66 7.76 
Uterus 21710 242 13366 1537 2546 1447 2572 1.11 61.57 7.08 11.73 6.67 11.85 70.74 8.13 13.48 7.66 
Table 3. Incidence numbers (column 2 = total, columns 3-7 = stages 0-IV, column 8 = stage unknown or “?”, for each row columns 3 
through 8 add up to column 2), incidence rates in % for stages 0-IV and stage unknown (columns 9-13 = stages 0-IV, column 14 = 
stage unknown, for each row columns 9 through 14 add up to 100% up to rounding to 2 digits), and incidence rates for stages I-IV 
only with stage 0 and stage unknown specifically excluded (columns 15-18 = stages I-IV, for each row columns 15 through 18 add up 
to 100% up to rounding to 2 digits).  The incidence numbers are based on the data for California adults aged 20 and older diagnosed 
with the cancers listed in column 1 during 2005-2009 as reported in [Morris et al, 2013].  Some cancer sites in column 1 are 
abbreviated as follows: Breast = female breast, Cervix = cervix uteri, Rectum = rectum and rectosigmoid junction, Kidney = kidney 
and renal pelvis, liver = liver and intrahepatic bile ducts, Lung = lung and bronchus, Melanoma = melanoma of the skin, Oral = oral 
cavity and pharynx, Bladder = urinary bladder, Uterine = uterine corpus.  For Bladder, stage I includes stage 0 (stage I = stage 0/I).
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Group Total, # Stage 
0, # 
Stage 
I, # 
Stage 
II, # 
Stage 
III, # 
Stage 
IV, # 
Stage 
?, # 
Stage 
0, % 
Stage 
I, % 
Stage 
II, % 
Stage 
III, % 
Stage 
IV, % 
Stage 
?, % 
Stage 
I, % 
Stage 
II, % 
Stage 
III, % 
Stage 
IV, % 
NHW 91951 17315 36067 23185 7899 3304 4181 18.83 39.22 25.21 8.59 3.59 4.55 51.19 32.91 11.21 4.69 
Black 8804 1634 2548 2533 1073 549 467 18.56 28.94 28.77 12.19 6.24 5.3 38.01 37.79 16.01 8.19 
Hispanic 22856 4155 6887 6663 2915 988 1248 18.18 30.13 29.15 12.75 4.32 5.46 39.46 38.18 16.7 5.66 
Asian/PI 16251 3818 5515 4353 1359 525 681 23.49 33.94 26.79 8.36 3.23 4.19 46.93 37.04 11.56 4.47 
Age 20-44 16560 3071 4245 5466 2445 627 706 18.54 25.63 33.01 14.76 3.79 4.26 33.21 42.76 19.13 4.9 
Age 45-64 69521 15088 24218 18211 6812 2590 2602 21.7 34.84 26.19 9.8 3.73 3.74 46.72 35.14 13.14 5 
Age 65+ 55573 9185 23052 13406 4103 2198 3629 16.53 41.48 24.12 7.38 3.96 6.53 53.91 31.35 9.6 5.14 
Table 4. Incidence numbers (column 2 = total, columns 3-7 = stages 0-IV, column 8 = stage unknown or “?”, for each row columns 3 
through 8 add up to column 2), incidence rates in % for stages 0-IV and stage unknown (columns 9-13 = stages 0-IV, column 14 = 
stage unknown, for each row columns 9 through 14 add up to 100% up to rounding to 2 digits), and incidence rates for stages I-IV 
only with stage 0 and stage unknown specifically excluded (columns 15-18 = stages I-IV, for each row columns 15 through 18 add up 
to 100% up to rounding to 2 digits).  The incidence numbers are based on the data for California women aged 20 and older 
diagnosed with Breast Cancer during 2005-2009 as reported in [Morris et al, 2013].  The demographic groups are abbreviated as 
follows: NHW = Non-Hispanic White, PI = Pacific Islander. 
 
Cancer Total, # Stage 
0, # 
Stage 
I, # 
Stage 
II, # 
Stage 
III, # 
Stage 
IV, # 
Stage 
?, # 
Stage 
0, % 
Stage 
I, % 
Stage 
II, % 
Stage 
III, % 
Stage 
IV, % 
Stage 
?, % 
Stage 
I, % 
Stage 
II, % 
Stage 
III, % 
Stage 
IV, % 
Breast 260590 49540 96601 67953 24317 10382 11797 19.01 37.07 26.08 9.33 3.98 4.53 48.48 34.1 12.2 5.21 
Colon 97947 8235 20085 23615 21597 17961 6454 8.41 20.51 24.11 22.05 18.34 6.59 24.12 28.36 25.94 21.57 
Rectum 30334 2814 7536 4794 6081 4242 4867 9.28 24.84 15.8 20.05 13.98 16.04 33.27 21.16 26.84 18.73 
Lung 155820 142 27008 7381 31097 69944 20248 0.09 17.33 4.74 19.96 44.89 12.99 19.94 5.45 22.96 51.65 
Prostate 198043 NA 16113 135698 14194 13359 18679 NA 8.14 68.52 7.17 6.75 9.43 8.98 75.66 7.91 7.45 
Table 5. Incidence numbers and rates with the same conventions for columns 2-18 as in Table 4.  The incidence numbers are based 
on the data for persons diagnosed with breast, colon, rectal, lung, and prostate cancer in California during 2004-2012 as reported in 
[Parikh-Patel et al, 2015].  Some cancer sites in column 1 are abbreviated as follows: Breast = female breast, Rectum = rectum and 
rectosigmoid junction, Lung = lung and bronchus.  
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Cancer Stage I, 
$ 
Stage II, 
$ 
Stage III, 
$ 
Stage IV, 
$ 
Stage I, 
% 
Stage II, 
% 
Stage III, 
% 
Stage IV, 
% 
Breast 29,377 40,989 57,155 67,038 52 32 10 6 
Prostate --- 26,505 30,541 44,591 --- 84 8 8 
Lung 60,038 73,509 84,726 93,166 22 4 26 48 
Colorectal 49,189 66,613 83,980 108,599 25 29 26 20 
Table 6. Medicare spending per patient in the first year after diagnosis (columns 2-5) and 
fractions of patients (columns 6-9) by stage at diagnosis based on California beneficiaries 
diagnosed in 2007-2011 and followed through 2012, as reported in [Schrag, 2015].  Spending 
estimates are based on Medicare fee-for-service patients only and are adjusted for inflation to 
2013 dollars.  For prostate cancer stages I and II are combined due to small numbers for stage I. 
 
Cancer Stage I, 
$ 
Stage II, 
$ 
Stage III, 
$ 
Stage IV, 
$ 
Stage I, 
% 
Stage II, 
% 
Stage III, 
% 
Stage IV, 
% 
Breast 64,889 70,931 71,555 70,057 27 32 19 22 
Prostate --- 66,160 82,621 71,704 --- 66 5 29 
Lung 82,621 78,091 74,186 65,907 13 3 27 57 
Colorectal 83,135 84,098 86,789 79,552 14 21 26 39 
Table 7. Medicare spending per patient in the last year of life (columns 2-5) and fractions of 
patients (columns 6-9) by stage at diagnosis based on California beneficiaries who were 
diagnosed in 2007-2011 and died in 2007-2012, as reported in [Schrag, 2015].  Estimates 
include the full year of Medicare spending prior to and including the month of death, 
irrespective of when the patient was diagnosed.  Spending estimates are based on Medicare 
fee-for-service patients only and are adjusted for inflation to 2013 dollars.  For prostate cancer 
stages I and II are combined due to small numbers for stage I. 
 
Cancer Average Costs, $ Average Cost-Savings, $ Average Cost-Savings, % 
Breast 38130 4330 11.35 
Prostate 28275 1770 6.26 
Lung 82897 20787 25.08 
Colorectal 75170 16623 22.11 
Table 8. Estimated average costs (second column), absolute cost-savings (third column) and 
relative cost-savings (in %, fourth column).  These estimates are based on the data in Table 6. 
 
Stage Average Costs, $ Incidence rate, % 
0 984 NA 
I 4259 52.1 
II 12566 32.6 
III 39761 9.7 
IV 42303 5.6 
IV (recurrent) 39281 NA 
Table 9. Average costs in the first year after diagnosis (second column) and incidence rates by 
stage at diagnosis (third column) for malignant melanoma based on 2008 data as reported in 
[Styperek and Kimball, 2012].  The incidence rates are given for stages I-IV and add up to 100%. 
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Cancer       
$ 
       
$ 
      
% 
        
$ 
       
$ 
          
% 
   
Breast* 90610 8489 9.37 82121 130909 0.5941 17.4 0.1034 
Breast 38130 4330 11.35 33801 60861 0.8006 16 0.1281 
Prostate 28275 1770 6.26 26505 37566 0.4173 16 0.0668 
Lung 82897 20787 25.08 62110 90201 0.4523 74 0.3347 
Colorectal 75170 16623 22.11 58546 94684 0.6172 46 0.2839 
Melanoma 12541 5085 40.55 7456 40691 4.4573 15.3 0.682 
Table 10. The quantities in columns 2-9 are defined in Subsection 6.1.  Row 2 corresponds to 
the commercial claims data of [Blumen et al, 2016].  Rows 3-6 correspond to the Medicare data 
of [Schrag, 2015].  Row 7 corresponds to the data reported in [Styperek and Kimball, 2012]. 
 
Cancer Estimated 
National 
Spending in 
2017, $M 
SD, % Estimated 
New Cases in 
2017, 
# 
Estimated 
Per-new-
incidence 
Spending in 
2017, $ 
          
% 
      
% 
Estimated 
National 
Cost-
savings, 
$M 
All Sites 152901.1 8.49 1688780 90539 --- --- --- 25902 
Bladder 4543.33 6.41 79030 57489 0.5202 12.42 6.07 276 
Brain 5604.18 11.58 23800 235470 0.5232 39.94 17.28 968 
Breast 19478.58 7.81 252710 77079 0.5941 17.4 9.37 1562 
Cervix 1441.05 10.69 12820 112406 0.5232 34.71 15.37 221 
Colorectal 15727.4 9.29 135430 116129 0.6172 46 22.11 3477 
Esophagus 1857.85 15.09 16940 109672 0.5232 60.99 24.19 449 
Oral 4101.55 9.34 49670 82576 0.5232 62.41 24.62 1010 
Kidney 5487.4 13.12 63990 85754 0.5232 33.36 14.86 815 
Leukemia 6772.22 8.72 62130 109001 0.5232 39.94 17.28 1170 
Lung 13693.22 11.31 222500 61543 0.4523 74 25.08 3434 
Lymphoma 15096.07 8.76 80500 187529 0.5232 39.94 17.28 2609 
Melanoma 3308.32 10.28 87110 37979 4.4573 15.3 40.55 1342 
Ovary 5338.73 11.32 22440 237911 0.5232 61.89 24.46 1306 
Pancreas 3040.12 16.06 53670 56645 0.5232 66.45 25.8 784 
Prostate 14873.72 5.47 161360 92177 0.4173 16 6.26 931 
Stomach 2074.28 11.88 28000 74081 0.5232 60.56 24.06 499 
Uterus 2947.42 9.08 61380 48019 0.5232 21.14 9.96 294 
Other 27515.67 10.11 275300 99948 0.5232 39.94 17.28 4755 
Table 11. Cancer site abbreviations in column 1 are the same as in Table 3.  Column 2 = mean 
estimated spending based on [NCI, 2017b] (which uses the “head-and-neck” nomenclature for 
Oral = oral cavity and pharynx cancer), and column 3 = standard deviation (see Subsection 6.2).  
Column 4 = number of estimated new incidences as reported in [ACS, 2017] and [Siegel et al, 
2017].  Column 5 = estimated per-new-incidence spending.  The factors   (column 6) and rate 
      (column 7) are taken from Table 10 for breast, colorectal, lung and prostate cancers and 
melanoma (bold font).  For other cancer sites the factor   is extrapolated from the values in 
Table 10 (italicized font) and rate       is taken from Table 3 (regular font) or extrapolated 
therefrom (italicized font).  See Subsection 6.1.  The relative cost-savings        (column 8) are 
obtained via Eq. (12) and Eq. (13), and cost-savings from early diagnosis (column 9) via Eq. (15), 
where the factor  is set to 1 for all cancer sites except breast cancer, for which         . 
